Chronic pain remains one of the most common—and most challenging—conditions encountered in community and health-system pharmacy practice. Pharmacists are increasingly expected to balance patient advocacy, regulatory compliance, opioid stewardship, clinical assessment, and documentation standards in an environment where both undertreatment of pain and inappropriate prescribing carry significant consequences.

While opioid prescribing rates have declined over the past decade, chronic pain prevalence continues to rise, particularly among older adults and patients with obesity, diabetes, autoimmune disease, neuropathy, orthopedic disorders, and post-surgical complications. At the same time, pharmacists face increasing scrutiny surrounding controlled substance dispensing, corresponding responsibility, prescription monitoring requirements, and identification of diversion patterns.

The modern pharmacist must now function as both a medication expert and a risk-management professional—while still maintaining compassionate patient care.

Understanding Chronic Pain in 2026

The Chronic Pain landscape has evolved significantly over the last decade. Current definitions generally describe chronic pain as pain lasting longer than three months or extending beyond normal tissue healing time. However, clinicians recognize chronic pain not simply as prolonged acute pain, but as a complex biopsychosocial condition involving neurologic, inflammatory, metabolic, musculoskeletal, and psychological components.

Common chronic pain conditions encountered in pharmacy practice include:

  • Osteoarthritis
  • Chronic low back pain
  • Fibromyalgia
  • Peripheral neuropathy
  • Migraine disorders
  • Pelvic pain disorders
  • Autoimmune and inflammatory pain syndromes
  • Cancer-related pain
  • Post-surgical pain syndromes

Pain perception is now understood to involve central sensitization, altered neurotransmitter signaling, neuroinflammation, stress-response dysregulation, and, in some patients, maladaptive neuroplasticity. This understanding has reinforced the need for multimodal, rather than exclusively opioid-based treatment approaches.

The Current Guideline Landscape

The release of the updated Centers for Disease Control and Prevention opioid prescribing guideline emphasized individualized care while attempting to reduce misapplication of earlier recommendations. Many clinicians interpreted the original 2016 guidance as rigid opioid ceilings, potentially contributing to abrupt discontinuation, forced tapering, and patient harm. The updated recommendations stress an individualized risk-benefit assessment through shared decision making. By utilizing ongoing assessments of function and quality of life, clinicians can use careful monitoring to avoid abrupt opioid discontinuation.

Importantly, the guideline emphasizes that dosage recommendations are guideposts rather than absolute mandates. For pharmacists, this reinforces the importance of clinical judgment, in addition to morphine milligram equivalent (MME) calculations as decision-making tools.

Acute Pain vs Chronic Pain: Why the Distinction Matters

Understanding whether a patient is experiencing acute, subacute, or chronic pain has major therapeutic implications.

Pain TypeTypical DurationCommon Goals
Acute Pain<1 monthRapid symptom relief and tissue healing
Subacute Pain1–3 monthsPrevent chronicity and restore function
Chronic Pain>3 monthsImprove function, quality of life, and symptom control

In chronic pain management, complete elimination of pain is often unrealistic. Treatment goals instead focus on:

  • Functional improvement
  • Improved sleep
  • Increased mobility
  • Reduction in pain flares
  • Improved participation in daily activities
  • Reduced reliance on high-risk medications

This distinction is critical when counseling patients who may expect complete pain resolution.

Red Flags vs Legitimate Chronic Pain: Avoiding Both Diversion and Patient Abandonment

One of the most difficult aspects of modern pharmacy practice involves balancing diversion prevention with compassionate patient care. While pharmacists must identify concerning prescribing or utilization patterns, overcorrection can lead to stigmatization or undertreatment of legitimate chronic pain patients.

Potential red flags may include:

  • Multiple overlapping opioid prescriptions
  • Early refill requests without explanation
  • Multiple prescribers or pharmacies
  • Traveling far distances to either the prescriber or pharmacy
  • Escalating doses without functional improvement
  • Prescribing combinations, including benzos, amphetamines, and/or muscle relaxants
  • Suspicious prescription alterations
  • Prescribing habits inconsistent with the type of medication
  • Cash payment patterns inconsistent with history

However, these findings should not automatically be interpreted as diversion.

Legitimate explanations may include:

  • Fragmented healthcare access
  • Insurance disruptions
  • Poorly controlled disease progression
  • Inadequate pain management
  • Pharmacogenomic drug metabolism
  • Geographic provider shortages
  • Care transitions after hospitalization or palliative care

Pharmacists should document objective observations, maintain professional communication with prescribers, and avoid emotionally charged or accusatory interactions. Prescribers may feel a pharmacist is questioning their prescribing ability. However, the responsibility falls on both prescribers and pharmacists to work together to prevent abuse and ensure patient care. Pharmacists should try to emphasize the importance of due diligence and the potential risks to all parties. Documenting these provider discussions is crucial for determining whether patients’ diagnosis and past prescribing are in line with the prescriber’s methodology for patient monitoring, scope of practice, and geography.

The Pharmacist’s Expanding Role in Pain Management

Pharmacists now play a substantially larger role in chronic pain management than simply dispensing medications.

Key pharmacist responsibilities increasingly include:

  • Evaluating therapeutic appropriateness
  • Identifying drug interactions
  • Assessing cumulative CNS depressant burden
  • Monitoring refill patterns
  • Counseling on naloxone use
  • Supporting opioid tapering plans
  • Recommending non-opioid alternatives
  • Improving adherence
  • Educating on safe storage and disposal
  • Encouraging realistic expectations regarding pain control

In many settings, pharmacists also serve as one of the final clinical checkpoints before medication reaches the patient. Non-opioid therapies should remain foundational in chronic pain management. They are often most effective when combined with physical, behavioral, and lifestyle interventions. But when opioids become necessary, pharmacists should normalize naloxone counseling similarly to epinephrine or rescue inhaler education to reduce stigma.

NSAIDs and Acetaminophen
Ibuprofen, naproxen, and acetaminophen remain commonly utilized first-line therapies for many musculoskeletal pain conditions. These may not be appropriate for patients with GI bleeding risk, renal or hepatic dysfunction, or those with cardiovascular risk. Patients should also be counseled to watch for duplicate ingredient exposure in OTC products. Topical NSAIDs may offer reduced systemic exposure while maintaining efficacy for localized osteoarthritis and soft tissue pain.

Topical Therapies
Topical therapies may provide meaningful relief with lower systemic risk. Common options include lidocaine, capsaicin, topical NSAIDs, and menthol-containing counterirritants. These products may be especially useful in older adults or polypharmacy patients. Patients should be reminded to wash hands to prevent transferring irritants to the eyes.

Antidepressants
Serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs) are commonly utilized in chronic pain management due to their effects on central pain signaling pathways.

Duloxetine remains one of the most evidence-supported nonopioid options for chronic musculoskeletal pain, diabetic peripheral neuropathy, fibromyalgia, and chronic low back pain. Other agents that may be utilized include venlafaxine, amitriptyline, and nortriptyline.

Selective serotonin reuptake inhibitors (SSRIs) generally demonstrate less consistent analgesic benefit compared with SNRIs and TCAs, but may still provide indirect improvement in pain perception when depression or anxiety are contributing factors.

Pharmacists should counsel patients regarding:

  • Sedation and daytime drowsiness
  • Orthostatic hypotension and fall risk
  • Dry mouth
  • Constipation
  • Urinary retention
  • Blurred vision
  • Cognitive impairment or confusion in older adults
  • Weight gain potential
  • Serotonergic interactions
  • Delayed onset of analgesic benefit

Particular caution should be exercised when using tricyclic antidepressants such as amitriptyline in older adults or in patients already taking multiple medications with anticholinergic properties, as cumulative anticholinergic burden may increase the risk of falls, delirium, and impaired cognition.

Pharmacists should also evaluate total anticholinergic load when reviewing chronic pain regimens, particularly in patients also receiving:

  • sedating antihistamines
  • bladder antispasmodics
  • muscle relaxants
  • antipsychotics
  • sleep aids
  • other centrally acting medications

Anticonvulsants
Gabapentin and pregabalin remain common for neuropathic pain syndromes. Dose adjustment in renal impairment remains essential. While sedation and the fall risk have long existed, pharmacists must also consider the risks of respiratory depression when combined with opioids and the growing concerns regarding potential misuse. Many states have scheduled gabapentin due to the risk of abuse, while others require reporting to the state’s prescription drug monitoring program (PDMP) even as a non-scheduled drug. Pharmacists should evaluate a patient’s PDMP profile to look for potential red flags with gabapentin co-prescribing.

Opioid Stewardship in Modern Practice
Opioids continue to play a role in select chronic pain patients, particularly those with cancer-related pain, palliative care, and severe refractory pain. However, opioid stewardship now requires ongoing monitoring rather than simple prescription fulfillment.

Key pharmacist considerations include:

  • Total daily MME assessment
  • Concurrent CNS depressants
  • Sedation risk
  • Sleep apnea risk factors
  • Naloxone co-dispensing
  • Functional improvement assessment
  • Constipation prevention
  • Signs of opioid-induced hyperalgesia

Buprenorphine: An Expanding Role
Buprenorphine continues to gain attention as a potentially safer analgesic option in certain patients due to partial mu-opioid agonist activity compared to full mu-opioid activity from other opiates. This provides a lower respiratory depression risk with a ceiling effect, where analgesic effects can continue increasing while respiratory suppression plateaus earlier. This can make buprenorphine effective in both pain management and opioid use disorder treatment.

Formulations may include transdermal patches, buccal films, and sublingual products. Buprenorphine (alone) carries greater risk of abuse and misuse than in combination with naloxone. Pharmacists should remain aware of formulation differences, DEA requirements, and payer restrictions that may vary across products.

Multimodal and Nonpharmacologic Approaches
Evidence increasingly supports multimodal chronic pain management strategies.

Nonpharmacologic interventions may include:

  • Physical therapy
  • Exercise therapy
  • Cognitive behavioral therapy
  • Weight management
  • Sleep optimization
  • Stress reduction techniques
  • Occupational therapy
  • Acupuncture
  • Mindfulness-based interventions

Pharmacists should consistently reinforce the concept that chronic pain management often requires multiple complementary interventions rather than reliance on a single medication.

Functional and Whole-Person Considerations
Many chronic pain patients also experience overlapping conditions involving:

  • Poor sleep quality
  • Metabolic dysfunction
  • Obesity
  • Depression
  • Anxiety
  • Inflammation
  • Sedentary lifestyle patterns

While pharmacists should avoid overstating evidence for alternative therapies, growing interest exists in supportive approaches involving anti-inflammatory nutrition patterns and vitamin deficiency correction.  Additional counseling on increasing even moderate physical activity, losing weight, optimizing sleep, and smoking cessation can be included.

Patients frequently seek guidance regarding supplements for pain and inflammation. Pharmacists can provide valuable counseling regarding efficacy, safety, drug interactions, and realistic expectations.

Protecting the Pharmacy While Supporting Patients
Modern chronic pain management requires pharmacies to develop clear, consistent workflows that reduce both regulatory and patient-care risk.

Best practices may include:

  • Consistent controlled substance policies and escalation pathways for concerns
  • Thorough documentation
  • Standardized pharmacist review processes
  • Professional prescriber communication
  • Staff education on stigma-free interactions
  • Routine PDMP utilization
  • Naloxone counseling protocols

Consistency is critical. Inconsistent enforcement of policies creates confusion, frustration, and potential liability exposure.

Revenue and Clinical Service Opportunities
Pain management continues to create opportunities for expanded pharmacy services.

Potential areas include:

  • Medication therapy management (MTM)
  • Naloxone education programs
  • Chronic care management support
  • Point-of-care testing (diabetes, A1c, hypertension, vitamin deficiency)
  • Medication synchronization
  • Sleep health counseling
  • Smoking cessation programs
  • Weight management services
  • OTC pain management consultations

As healthcare systems increasingly emphasize outcomes and preventive care, pharmacists remain well positioned to support chronic pain patients through both medication expertise and longitudinal patient relationships.

Key Takeaways

  • Chronic pain management requires individualized, multimodal approaches.

  • Pharmacists play a critical role in balancing patient care with regulatory compliance.

  • Red flags should prompt assessment—not automatic assumptions of diversion.

  • Non-opioid therapies remain foundational in chronic pain treatment.

  • Opioid stewardship involves ongoing monitoring, documentation, and patient education through consistent pharmacy workflows

As chronic pain management continues to evolve, pharmacists will continue to serve a key role improving both safety and quality of life for patients navigating complex pain conditions.

References: